<DOC>
	<DOCNO>NCT02219256</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetic safety tolerability profile TAK-079 follow single intravenous ( IV ) infusion subcutaneous administration escalate dose level healthy participant .</brief_summary>
	<brief_title>A Phase 1 Study Assess Safety , Tolerability , Pharmacokinetics TAK-079 Healthy Subjects</brief_title>
	<detailed_description>The drug test study TAK-079 . TAK-079 test find safe well-tolerated dose assess TAK-079 process body . This study look pharmacokinetics , side effect , laboratory result people take TAK-079 design randomized single dose-rising study . Therefore , subsequent cohort start previous cohort complete result review . Each participant receive TAK-079 placebo intravenous infusion . The start dose 0.0003 mg/kg . If dose well-tolerated , next group receive high dose , etc , maximal tolerate dose reach high dose exceed 1.0 mg/kg . This single-center trial conduct United Kingdom . The overall time participate study 17 week . Participants make 11 visit clinic , include one 10-day period confinement clinic . All participant contact telephone 14 day last visit clinic follow-up assessment .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>1 . Is healthy male female child bear potential 18 55 year age inclusive . 2 . 2 . The subject weigh least 70 kg cohort 1 subsequent cohort 50 kg ( 110.2 lb ) less 100 kg ( 220.5 lb ) body mass index ( BMI ) range 18.5 30 kg/m2 , inclusive Screening Visit 1 . 3 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 6 month last dose study medication . 1 . Has receive investigational compound within last 3 month 5Ã—T1/2 investigational compound , whichever longer , prior day study medication ( Day 1 ) . 2 . Has receive live vaccination , within last 3 month prior Screening expect receive vaccination study 1 month Day 78 Study Exit visit . 3 . Has receive biologic medical product time past . 4 . Has positive drug alcohol screen result , history drug alcohol abuse . 5 . Has positive test result hepatitis human immunodeficiency virus antibody . 6 . Has sign acute infection history frequent chronic infection , herpes zoster . 7 . Has active latent tuberculosis ( TB ) 8 . Considered unfit study Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>